TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
26/12/2024
Voltar para busca
Dado oficial do USPTO
DXT
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
30
Atualização mais recente
31/12/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 9, 42
Data de depósito
12/04/2022
Data de registro
19/12/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
19/12/2023
Última transação
31/12/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
09
Localização do titular
IT
Examinador
YOO, JEANE
Unidade examinadora
N20
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
DOMPE' FARMACEUTICI S.P.A.
Representantes
Theodore R. Remaklus Thompson Hine LLP
Classificação técnica
Classes Nice
Classe 5Classe 9Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparation for the treatment of respiratory diseases; pharmaceutical preparation for the treatment of bone diseases; analgesic and muscle relaxant pharmaceutical preparations; antibacterial pharmaceuticals; anti-epileptic pharmaceutical preparations; balms for pharmaceutical purposes; capsules sold empty for pharmaceuticals; cardiovascular pharmaceutical preparations; ocular pharmaceuticals; pharmaceutical products for ophthalmological use; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for the prevention and treatment of rare ocular disorders or diseases; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases; pharmaceutical antitussive cold preparations; pharmaceutical preparations for use in chemotherapy; pharmaceutical products for the treatment of viral and infectious diseases; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in the treatment of rare tissue and organ transplantation-related diseases and conditions; pharmaceutical preparations for use in tissue and organ transplantation; pharmaceutical preparationsanticoagulants; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for peripheral nervous system; pharmaceutical preparations for the treatment of rare diabetes-related conditions; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for the treatment of bacteria-based diseases; pharmaceutical preparationsantiviral preparationsantibioticsantifungal preparations and vaccines; pharmaceutical preparations and substances for the treatment of infectious diseasesblood disorderspaininflammationsepsis; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparationsan analgesic for human consumption taken orally; disinfectants for hygiene purposes; none of the foregoing for use with blood-related cell processing devicesblood-related medical and laboratory devicesblood-related software and technologyblood-related medical device and data management systems for peripheral nervous system; pharmaceutical preparations for the treatment of rare diabetes-related conditions; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for the treatment of bacteria-based diseases; pharmaceutical preparationsantiviral preparationsantibioticsantifungal preparations and vaccines; pharmaceutical preparations and substances for the treatment of infectious diseasesblood disorderspaininflammationsepsis; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparationsan analgesic for human consumption taken orally; disinfectants for hygiene purposes; none of the foregoing for use with blood-related cell processing devicesblood-related medical and laboratory devicesblood-related software and technologyblood-related medical device and data management systems
Classe 9
Downloadable computer software for use in identifying new drugs; downloadable computer software for use by doctors and other medical professionals in capturingtrackingreportinganalyzing health data for use in making informed medical decisions; downloadable virtual reality software for medical teaching; downloadable virtual reality software for medical screening; downloadable computer software platforms for use in database management in the field of medicine; downloadable computer application software for mobile phonessoftware for use in identifying new drugs; downloadable computer software using artificial intelligence for use in identifying new drugs; none of the foregoing for use with blood-related cell processing devicesblood-related medical and laboratory devicesblood-related software and technologyblood-related medical device and data management systems
Classe 42
Software as a service (SAAS) services featuring software using artificial intelligence for use in identifying new drugs; providing a website featuring non-downloadable software using artificial intelligence for use in identifying new drugs; research in the field of artificial intelligence; design and development of computer software in the field of medicine; design and development of virtual reality software for medical screening; design and development of virtual reality software for medical teachingnone of the foregoing for use with blood-related cell processing devicesblood-related medical and laboratory devicesblood-related software and technologyblood-related medical device and data management systems
Publicações
Histórico de despachos e eventos da marca no USPTO.
30 publicações encontradas
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
26/12/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
26/12/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
26/12/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
26/12/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
23/04/2024
FICS
FINAL DISPOSITION NOTICE SENT TO IB
29/03/2024
FIMP
FINAL DISPOSITION PROCESSED
29/03/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
19/03/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
19/12/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
19/12/2023
GPNX
NOTIFICATION PROCESSED BY IB
04/10/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/10/2023
PUBO
PUBLISHED FOR OPPOSITION
03/10/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
13/09/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
13/09/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
13/09/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
30/08/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/08/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/08/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/08/2023
RFNT
REFUSAL PROCESSED BY IB
20/04/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
29/03/2023
RFRR
REFUSAL PROCESSED BY MPU
29/03/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/02/2023
CNRT
NON-FINAL ACTION WRITTEN
03/02/2023
DOCK
ASSIGNED TO EXAMINER
30/01/2023
MAFR
APPLICATION FILING RECEIPT MAILED
13/09/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/09/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/09/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace DXT ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.